Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2023, Vol. 28 ›› Issue (11): 1307-1314.doi: 10.12092/j.issn.1009-2501.2023.11.014

Previous Articles     Next Articles

Interactions and clinical significance of gut microbiota and levothyroxine

ZHOU Jiating1,2,3,4, ZHANG Xuan5, XIE Zilan1,2,3,4, LI Zhi1,2,3,4   

  1. 1Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410078, Hunan, China; 2Institute of Clinical Pharmacology, Central South University and Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, Hunan, China; 3Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha 410078, Hunan, China; 4National Clinical Research Center for Geriatric Disorders, Changsha 410078, Hunan, China; 5 General Surgery Department of the Second People's Hospital  of  Hunan, Changsha 410078, Hunan, China
  • Received:2023-04-24 Revised:2023-07-23 Online:2023-11-26 Published:2023-11-10

Abstract:

Levothyroxine is a class of thyroid hormone medication mainly used in the clinical treatment of thyroid hormone replacement therapy and thyrotropin suppression therapy. In recent years, studies have found a close correlation between the human gut microbiota and the occurrence and development of thyroid diseases, as well as changes in thyroid hormone levels. Therefore, understanding the impact of levothyroxine on the gut microbiota, as well as the effects of the gut microbiota on the metabolism and absorption of levothyroxine, is of great significance for the treatment of thyroid diseases and the rational use of clinical medication. This article explores the interaction between the gut microbiota and levothyroxine and summarizes the current clinical findings of the gut microbiota in levothyroxine therapy.

Key words: levothyroxine, gut microbiota, pharmacokinetics, clinical medication

CLC Number: